Therapeutic apheresis is used to treat various types of disorders. The American Society for Apheresis (ASFA) publishes evidence-based guidelines every 3 years to assist apheresis practitioners in the rationale and management of apheresis patients and outlines basic technical specifications for procedures. However, the ASFA guidelines on the use of therapeutic apheresis published by the Journal of Clinical Apheresis only include indications that have enough evidence in the medical literature to provide apheresis recommendations. The guidelines do not include all the diseases that were reported in the medical literature or the ones that may be potentially treated by apheresis in the future. For new factsheet development, the committee responsible for developing the ASFA guidelines review requests from apheresis practitioners. One or more committee members will evaluate the available literature for evidence for the use of therapeutic apheresis in the disease or indication. A minimum of 10 cases, preferably by at least 2 groups, published in the last decade in peer-reviewed journals. In the current version of the ASFA guidelines (2019), the committee considered several potential new indications; however, none of them had enough evidence to be included in the current guidelines as new factsheets. Of note, the committee will review and issue interim factsheets for new indications if necessary before the release of the next version of the guidelines. Furthermore, due to COVID-19 pandemic, the next version of the ASFA Guidelines will be released in 2023.